argenx reports positive FB102 Phase 2 results: stock ahead of Xetra open at prior close EUR 829.70
Published on 10/08/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx SE announced positive topline results from a Phase 2 study of FB102 in adults with celiac disease on October 8, 2026. The study met its primary endpoint, according to the argenx release carried by Yahoo Finance. Ahead of the Xetra open, the October 7, 2026, prior close at Lang & Schwarz was EUR 829.70.
Pre-market indication
Lang & Schwarz showed no new trading indication for argenx before the Xetra session on October 8, 2026. The reference level remained the EUR 829.70 closing price from October 7, 2026. The first price of the day is shown from the start of trading by the continuously updated real-time quote of argenx stock.
FB102 study reaches primary endpoint
Patients receiving FB102 showed a statistically significant treatment effect versus placebo. The primary endpoint measured the change from baseline in the villus height-to-crypt depth ratio at day 78 during a controlled gluten challenge, with a p-value of 0.0176. Additional measures, including intraepithelial lymphocyte density, a composite histology score and symptoms, were consistent with the primary endpoint. The company said the safety profile was consistent with prior studies and that no new safety signals were identified. The published release said argenx plans to advance FB102 into Phase 3 development.
Separate UNITY update
In a separate October 8 announcement, argenx said it will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease. An Independent Data Monitoring Committee recommended stopping the study for futility after an interim analysis and concluded that UNITY could not meet its primary endpoint. Argenx said safety was consistent with efgartigimod's established profile and that no new safety signals were identified, according to Business Insider.
Study design
The FB102-301 study enrolled 126 patients with confirmed celiac disease who had been symptom-free on a strict gluten-free diet for at least 12 months. Participants received intravenous FB102 at two dose levels or placebo in a 2:2:1 randomization while undergoing an eight-week oral gluten challenge. Detailed results are expected at an upcoming medical meeting, the company release said.
